# Clinical Evaluation of the New Hypoxia Imaging Agent HX4

> **NCT01213030** · PHASE1,PHASE2 · COMPLETED · sponsor: **Siemens Molecular Imaging** · enrollment: 12 (actual)

## Conditions studied

- Head and Neck Cancer
- Lung Cancer
- Liver Cancer

## Interventions

- **DRUG:** [F-18] FMISO
- **DRUG:** [F-18] HX4

## Key facts

- **NCT ID:** NCT01213030
- **Lead sponsor:** Siemens Molecular Imaging
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213030, "Clinical Evaluation of the New Hypoxia Imaging Agent HX4". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01213030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*